Abstract
Quantitation of reactive intermediates from bioactivation of drug via covalent protein binding using radiolabeled drug is the gold standard for quantitation of reactive metabolite formation in the absence of synthetic standard. However, radiolabeling many compounds during lead optimization can be resource intensive and expensive, which led to development of alternative method for quantitation of reactive metabolites using trapping agents as a surrogate to covalent protein binding. Quantitation of reactive metabolite formation using trapping agents can be broadly divided into two categories: (1) Radiolabeled trapping agents such as [35S]-cysteine, [35S]-glutathione, [3H]-glutathione and [14C]-cyanide. In general, the concentration of the radiolabeled adducts of reactive intermediates can be calculated from the peak area in dpm and the specific activity. (2) Non-radiolabeled trapping agents such as dansyl glutathione and quaternary ammonium glutathione analogs. Here quantitation is based on the intrinsic spectroscopic property of the chemical tag, for example, the dansyl glutathione adduct is quantitated using the emission and excitation wavelength of the fluorescence dansyl moiety. On the other hand, quantitation of quarternary ammonium glutathione conjugate is dependent on the similarity in MS responses of the precursor molecular ion and similar efficiency in formation of the product ion containing the quarternary ammonium moiety of analyte and internal standard. In this chapter, we will describe the experimental procedures for quantitation of reactive metabolite formation using these trapping agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Liebler DC, Guengerich FP (2005) Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 4:410–420
Walgren JL, Mitchell MD, Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35:325–361
Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889–893
Evans DC, Baillie TA (2005) Minimizing the potential for metabolic activation as an integral part of drug design. Curr Opin Drug Discov Devel 8:44–50
Amacher DE (2006) Reactive intermediates and the pathogenesis of adverse drug reactions: the toxicology perspective. Curr Drug Metab 7:219–229
Doss GA, Baillie TA (2006) Addressing metabolic activation as an integral component of drug design. Drug Metab Rev 38:641–649
Tang W (2007) Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 3:407–420
Caldwell GW, Yan Z (2006) Screening for reactive intermediates and toxicity assessment in drug. Curr Opin Drug Discov Devel 9:47–60
Uetrecht J (2003) Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 8:832–837
Day SH, White R, Schulz-Utermoehl T, Miller R, Beconi MG (2005) A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods 52:278–285
Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16
Masubuchi N, Makino C, Murayama N (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediates: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and human. Chem Res Toxicol 20:455–464
Mulder GJ, Le CT (1988) A rapid, simple in vitro screening test, using [3H]glutathione and L-[35S]cysteine as trapping agents, to detect reactive intermediates of xenobiotics. Toxicol In Vitro 2:225–230
Hartman NR, Cysyk RL, Bruneau-Wack C, Thenot JP, Parker RJ, Strong JM (2002) Production of intracellular 35S-glutathione by rat and human hepatocytes for the quantification of xenobiotics reactive intermediates. Chem Biol Interact 142:43–55
Takakusa H, Masumoto H, Makino C, Okazaki O, Sudo K (2009) Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab Pharmacokinet 24(1):100–107
Inoue K, Shibata Y, Ttakahashi H, Ohe T, Chiba M, Ishii Y (2009) A trapping method for semi-quantitative assessment of reactive metabolite formation using [35S]Cysteine and [14C]Cyanide. Drug Metab Pharmacokinet 24(3):245–254
Gan J, Harper TW, Hsueh MM, Qu Q, Humphreys WG (2005) Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol 18:896–903
Gan J, Ruan Q, He B, Zhu M, Shyu WC, Humphreys WG (2009) In vitro screening of 50 highly prescribed drugs for thiol adduct formations. Comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 22:690–698
Soglia RJ, Contillo GL, Kalgutkar SA, Zhao S, Hop ECAC, Boyd GJ, Cole JM (2006) A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem Res Toxicol 19:480–490
Hinson JA, Reid AB, McCullough SS, James LP (2004) Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 36:805–822
Maggs JL, Williams D, Pirmohamed M, Park BK (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 275:1463–1475
Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366–372
Acknowledgements
The views expressed here are solely those of the author and do not reflect the opinions of Janssen Research & Development, LLC.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Chen, J., Xu, R.F., Lam, W.W., Silva, J., Lim, HK. (2014). Quantitative Assessment of Reactive Metabolites. In: Caldwell, G., Yan, Z. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-742-6_29
Download citation
DOI: https://doi.org/10.1007/978-1-62703-742-6_29
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-741-9
Online ISBN: 978-1-62703-742-6
eBook Packages: Springer Protocols